Dual inhibition of mTORC1/C2 and HER2 results in maximal antitumor efficacy in preclinical model of HER2+breast cancer resistant to trastuzumab therapy

被引：1
|
作者：
De, Pradip Kr [1 ]
Sun, Yuliang [1 ]
Carlson, Jennifer H. [1 ]
Lin, Xiaoqian [1 ]
Dey, Nandini [1 ]
Leyland-Jones, Brian [1 ]
机构：
[1] Avera Res Inst, Sioux Falls, SD USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1940
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1940
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Dual targeting of HER2: Enhanced antitumor efficacy of trastuzumab-DM1 combined with pertuzumab
    Fields, Carter T.
    Crocker, Lisa M.
    Sliwkowski, Mark X.
    Phillips, Gail D. Lewis
    CANCER RESEARCH, 2010, 70
  • [22] HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+breast cancer
    Green, Andrew R.
    Barros, Fabricio F. T.
    Abdel-Fatah, Tarek M. A.
    Moseley, Paul
    Nolan, Christopher C.
    Durham, Alice C.
    Rakha, Emad A.
    Chan, Stephen
    Ellis, Ian O.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (01) : 33 - 44
  • [23] In vitro potency of dual PI3K/mTORC1/C2 inhibitor, GDC-0980 in ER+ and HER2 overexpressing breast cancer cells
    Sun, Yuliang
    De, Pradip
    Carlson, Jennifer H.
    Friedman, Lori
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2015, 75
  • [24] Trastuzumab sensitizes HER2+breast cancer to increase efficacy of chemotherapy in vitro and in vivo
    Shah, Alay
    Jarrett, Angela
    Syed, Anum
    Yankeelov, Thomas
    Sorace, Anna
    CANCER RESEARCH, 2019, 79 (13)
  • [25] Notch-1 mediated down regulation of PTEN in trastuzumab resistant HER2+breast cancer
    Baker, Andrew T.
    Pandya, Kinnari
    Osipo, Clodia
    CANCER RESEARCH, 2016, 76
  • [26] HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab
    Ithimakin, Suthinee
    Day, Kathleen C.
    Malik, Fayaz
    Zen, Qin
    Dawsey, Scott J.
    Bersano-Begey, Tom F.
    Quraishi, Ahmed A.
    Ignatoski, Kathleen Woods
    Daignault, Stephanie
    Davis, April
    Hall, Christopher L.
    Palanisamy, Nallasivam
    Heath, Amber N.
    Tawakkol, Nader
    Luther, Tahra K.
    Clouthier, Shawn G.
    Chadwick, Whitney A.
    Day, Mark L.
    Kleer, Celina G.
    Thomas, Dafydd G.
    Hayes, Daniel F.
    Korkaya, Hasan
    Wicha, Max S.
    CANCER RESEARCH, 2013, 73 (05) : 1635 - 1645
  • [27] New quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer
    Schroeder, Richard L.
    Simmons, Darinique
    Thompson, Jasmine
    Sridhar, Jayalakshmi
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [28] Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer
    Sridhar, Jayalakshmi
    Sfondouris, Mary E.
    Bratton, Melyssa R.
    Nguyen, Thuy-Linh K.
    Townley, Ian
    Stevens, Cheryl L. Klein
    Jones, Frank E.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (01) : 126 - 131
  • [29] Antitumor properties of bromelain loaded trastuzumab conjugated niosomes in HER2+breast cancer cells
    Tut, Ezgi
    Guldu, Ozge Kozgus
    Medine, Emin Ilker
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 101
  • [30] HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab
    Maiik, Fayaz
    Ithimakin, Suthinee
    Day, Kathleen
    Ignatoski, Kathy
    Zen, Qin
    Thomas, Dafydd
    Bersano, Tom
    Dawsey, Scott
    Hall, Christopher
    Davis, April
    Quraishi, Ahmed A.
    Tawakkol, Nader
    Clouthier, Shawn G.
    Day, Mark
    Hayes, Daniel F.
    Korkaya, Hasan
    Wicha, Max S.
    CANCER RESEARCH, 2012, 72
12345